SecBot SecBot
Biotech Drug Report Generated Nov 12, 2026

dabogratinib

TYRA·Tyra Biosciences, Inc.
MIXED
Drug Impact Rating6/10
Trial phase
Phase 2
Time to market
Dabogratinib is in Phase 2 development across all three indications. A pivotal Phase 3 study in NMIBC is being planned following the SURF302 data, but no specific start date has been given. The earliest potential approval would likely be several years away, contingent on successful Phase 3 data and FDA review.
Why 6/10
The next hard catalyst is the BEACH301 Phase 2 safety sentinel cohort data in pediatric achondroplasia, expected by end of Q1 2027 (~4-5 months from now). This is an early safety/efficacy readout on the company's only clinical-stage drug, but it is a sentinel cohort rather than a full pivotal readout, so the binary impact is moderate.
Actionable Insight MIXED

The next hard catalyst is the BEACH301 Phase 2 safety sentinel cohort data in pediatric achondroplasia, expected by end of Q1 2027. Positive safety and growth data could re-rate the stock after the September 2026 SURF302 selloff; negative safety signals would damage the achondroplasia thesis. Separately, watch for details on a planned pivotal Phase 3 study in NMIBC, which would be the next major binary event for the bladder cancer program.

Price Chart

Loading chart...

Executive Summary

Dabogratinib (formerly TYRA-300) is Tyra Biosciences' only clinical-stage asset, an oral FGFR3-selective inhibitor being developed across three indications: low-grade upper tract urothelial carcinoma (LG-UTUC), intermediate-risk non-muscle invasive bladder cancer (IR NMIBC), and pediatric achondroplasia. Initial Phase 2 SURF302 data in NMIBC reported September 9, 2026 showed a 79% overall response rate and 64% complete response rate with a clean safety profile, but the stock fell ~30% as the market expected stronger efficacy. The company completed a $400M equity offering in September 2026 and held $700.5M in cash as of Q3 2026, funding operations through 2030. The next catalyst is the BEACH301 Phase 2 safety sentinel cohort data in achondroplasia, expected by end of Q1 2027.

How It Works

Dabogratinib is an oral pill that blocks FGFR3, a protein on the surface of cells that can drive abnormal cell growth when mutated. By selectively inhibiting FGFR3, the drug aims to shrink tumors in bladder cancers that carry FGFR3 mutations. It is also being tested in achondroplasia (dwarfism), where overactive FGFR3 signaling stunts bone growth; blocking it may allow more normal bone development in children.

Trial Status

Three ongoing clinical programs: SURF302 (Phase 2 in FGFR3-altered LG IR NMIBC) reported initial data in September 2026 with a 79% ORR and 64% CR rate at 60 mg QD; BEACH301 (Phase 2 in pediatric achondroplasia) is enrolling with safety sentinel cohort data expected end of Q1 2027; SURF301 (Phase 1/2 in metastatic urothelial cancer) is ongoing with an ASCO 2026 abstract on ctDNA monitoring.

The Two-Sided Case

▲ Bull Case5
Initial SURF302 Phase 2 data showed a 79% overall response rate and 64% complete response rate at 60 mg QD in FGFR3-altered LG IR NMIBC, with a clean safety profile (no hyperphosphatemia, nail or ocular toxicity; Grade 3 AEs in <5% of patients).
Dabogratinib is designed to be more FGFR3-selective than J&J's Balversa (erdafitinib), potentially avoiding the class-wide toxicities that limit existing FGFR inhibitors.
Analyst consensus is strongly bullish: 10 Buy vs 2 Hold (0 Sell), with a mean price target of $47.45, implying ~113% upside from the current ~$20.97 price.
The company has a cash runway through 2030 with $700.5M on hand after a $400M equity raise, providing ample funding to advance all three programs without near-term financing risk.
Strong institutional accumulation in Q2 2026 from major funds including BlackRock, T. Rowe Price (doubled), State Street, Vanguard, and new position from Hood River Capital.
▼ Bear Case5
The stock dropped ~30% on September 9, 2026 after initial SURF302 Phase 2 data, suggesting the market expected stronger efficacy despite a 79% ORR and 64% CR rate. Investor skepticism about the drug's profile persists.
Dabogratinib is Tyra's only clinical-stage asset; any clinical setback would leave the company with no pipeline, making it a high-risk single-asset story.
Several large institutional holders trimmed or exited in Q2/Q3 2026, including Farallon Capital Management (exit), Balyasny (exit), and Barclays (near-exit), signaling mixed conviction.
The BEACH301 achondroplasia program is still early (safety sentinel cohort of ~25 children) with no efficacy data yet; pediatric bone-growth trials are notoriously difficult and carry long timelines.
A $400M September 2026 equity offering diluted existing shareholders, and the company is still burning ~$51M/quarter with no approved products or revenue.

Upcoming Catalysts

  • BEACH301 Phase 2 safety sentinel cohort initial data in pediatric achondroplasia: expected end of Q1 2027
  • Potential announcement of pivotal Phase 3 study design/initiation in NMIBC
  • Additional SURF302 data updates at medical conferences
  • SURF301 Phase 1/2 data updates in metastatic urothelial cancer

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Tyra Biosciences, Inc. 8-K TYRA ·Originating report

Sources · 9

Hover a chip for the title
1 prnewswire.com2 msn.com3 fiercebiotech.com4 prnewswire.com5 marketscreener.com6 seekingalpha.com7 cancernetwork.com8 prnewswire.com9 prnewswire.com